CTPS2

Across TCGA pan-cancer cohorts, CTPS2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CTPS2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CTPS2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CTPS2 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where CTPS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CTPS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.325	<.001	11	view →
HNSC	Male	All	−0.175	.001	6	view →
LSCC	Male	II,III,IV	−0.207	<.001	5	view →
PDAC	Male	III,IV	+0.395	.030	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CTPS2–CCRCC

Open the CCRCC breakdown →